ESR2 and neoplasm: This trend was also observed when patients were stratified by tumor ESR2 expression, with patients with higher than median ESR2 expression (ESR2 > 3.69) (Fig. 5B) having significantly higher survival rates than patients with lower ESR2 expression after 15 years.